8.44
8.44 (0%)
As of Apr 17, 2025
Exicure, Inc. [XCUR]
Source:
Company Overview
Exicure, Inc. have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
| Country | United States |
| Headquarters | chicago, illinois |
| Phone Number | 847-673-1700 |
| Industry | manufacturing |
| CEO | Paul Kang |
| Website | www.exicuretx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.5 |
| Operating Profit | $-12.2 |
| Net Income | $-9.7 |
| Net Cash | $10.5 |
Profit Ratios
| Gross Margin | $0.5 |
| Operating Margin | -2,446.4 |
| Profit as % of Revenues | -5.2% |
| Profit as % of Assets | -72.8% |
| Profit as % of Stockholder Equity | -143.3% |
Management Effectiveness
| Return on Equity | -143.3% |
| Return on Assets | -64.4% |
| Turnover Ratio | 3.8% |
| EBITA | $-12.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $15.1 |
| Total Liabilities | $8.3 |
| Operating Cash Flow | $-2.9 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $13.4 |
